alexa Comparison of treatment response in second-episode versus first-episode schizophrenia.
Psychiatry

Psychiatry

Journal of Neuropsychopharmacology & Mental Health

Author(s): Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L, Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L

Abstract Share this page

Abstract This study investigated whether illness progression and treatment refractoriness emerge after relapse in schizophrenia. We compared outcomes in a cohort treated with a standardized protocol for the first and second episodes of illness. The sample comprised 31 participants who (1) had successfully completed a 2-year open-label treatment phase with risperidone long-acting injection (RLAI) for a first episode of schizophrenia; (2) underwent an intermittent treatment extension phase up to 3 years or until recurrence, and (3) entered a further 2-year treatment phase with RLAI for a recurrence episode. For the patients who remained in treatment (n = 14 [45\%]), Positive and Negative Syndrome Scale score reductions, response rates, remission rates, time to response, time to remission, functional outcome scores, and modal RLAI doses were similar for the 2 treatment periods. However, 17 (55 \%) of the 31 patients discontinued the study in the second episode compared with 14 (28\%) of 50 patients in the first episode, suggesting reduced effectiveness of antipsychotics when reintroduced after illness recurrence. Most notably, emergent treatment nonresponsiveness was observed in 5 participants (16\%), consistent with the hypothesis that relapse may be biologically harmful in a subset of patients. This article was published in J Clin Psychopharmacol and referenced in Journal of Neuropsychopharmacology & Mental Health

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords